Search

Search Constraints

You searched for: Author/Creator Wright, Samuel D.

Search Results

3. CSL112 (Apolipoprotein A-I [Human]) Strongly Enhances Plasma Apoa-I and Cholesterol Efflux Capacity in Post-Acute Myocardial Infarction Patients: A PK/PD Substudy of the AEGIS-I Trial. (25th October 2022)

4. Enhanced HDL Functionality in Small HDL Species Produced Upon Remodeling of HDL by Reconstituted HDL, CSL112: Effects on Cholesterol Efflux, Anti-Inflammatory and Antioxidative Activity. Issue 6 (2nd September 2016)

5. Infusion of Reconstituted High‐Density Lipoprotein, CSL112, in Patients With Atherosclerosis: Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical Trial. Issue 8 (25th August 2015)

6. Infusion of Reconstituted High‐Density Lipoprotein, CSL112, in Patients With Atherosclerosis: Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical Trial. Issue 8 (August 2015)

9. Pharmacokinetics and Safety of CSL112 (Apolipoprotein A‐I [Human]) in Adults With Moderate Renal Impairment and Normal Renal Function. Issue 5 (21st September 2018)

10. Pharmacometric analyses to characterize the effect of CSL112 on apolipoprotein A‐I and cholesterol efflux capacity in acute myocardial infarction patients. Issue 6 (23rd December 2020)